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Abstract  58 
Nausea and vomiting of pregnancy (NVP) is a common condition that affects as 59 
many as 70% of pregnant women. Although no consensus definition is available 60 
for hyperemesis gravidarum (HG), it is typically viewed as the severe form of 61 
NVP and has been reported to occur in 0.3–10.8% of pregnant women. HG can 62 
be associated with poor maternal, fetal and child outcomes. The majority of 63 
women with NVP can be managed with dietary and lifestyle changes, but more 64 
than one-third of patients experience clinically relevant symptoms that may 65 
require fluid, vitamin supplementation and/or antiemetic therapy; for example, 66 
combined doxylamine/pyridoxine is not teratogenic and may be effective in 67 
treating NVP. Ondansetron is commonly used to treat HG, but studies are 68 
urgently needed to determine whether it is safer and more effective than using 69 
first-line antiemetics. Thiamin (vitamin B1) should be introduced following 70 
protocols to prevent refeeding syndrome (the sudden shifts in fluids and 71 
electrolytes following a period of starvation) and Wernicke encephalopathy. 72 
Recent advances in the genetic study of NVP and HG suggest a placental 73 
component to the aetiology by implicating common variants in genes encoding 74 
placental proteins (namely GDF15 and IGFBP7) and hormone receptors (namely 75 
GFRAL and PGR). New studies on aetiology, diagnosis, management, and 76 
treatment are under way. In the next decade, progress in these areas may 77 
improve maternal quality of life and limit adverse outcomes associated with HG.  78 
 79 
[H1] Introduction  80 
Nausea and vomiting of pregnancy (NVP) is common, usually begins during 81 
pregnancy weeks 6-8 and generally subsides by 16–20 weeks gestation1. Severe 82 
3 
 
NVP, or hyperemesis gravidarum (HG), is the leading cause of hospitalization in 83 
the first trimester and the second-most common indication for pregnancy 84 
hospitalization overall2. The term ‘hyperemesis gravidarum’ is likely to have first 85 
appeared in medical literature in 1898 (Ref3), although reports on NVP date back 86 
to ancient Egyptian times; the first death from vomiting in pregnancy was 87 
reported in 1706 (Ref4). Until intravenous fluids were introduced, HG incurred a 88 
high risk of maternal mortality4. In 1956, a panel appointed by the American 89 
Council on Pharmacy and Chemistry first defined HG as intractable vomiting and 90 
disturbed nutrition, with for example altered electrolyte balance, weight loss of 91 
≥5%, ketosis and acetonuria, with ultimate neurological disturbances, liver 92 
damage, retinal haemorrhage and renal damage. In 1968, the distinction 93 
between mild or moderate NVP and HG was noted to be unclear and has 94 
remained challenging4. Even now, an international definition setting out the 95 
‘boundaries’ of HG has yet to be established5, but general guidelines can be 96 
applied to most cases (Table 1). A practical clinical use of these terms is that the 97 
most severe form of NVP with complications such as dehydration or metabolic 98 
deficiencies (weight loss, electrolyte deficiencies or malnutrition) will constitute 99 
HG.  100 
 101 
The past belief that HG is self-limiting and does not have long-term 102 
consequences is incorrect. Although overall maternal and child outcomes are 103 
favourable, the past decade has produced a body of knowledge to support the 104 
assertion that HG can be associated with poor maternal and fetal sequelae and 105 
can be, in rare cases, a cause of maternal and fetal death6. Generally, the clinical 106 
presentation of HG includes severe intractable vomiting, often associated with 107 
>5% weight loss, dehydration, ketonuria, nutritional deficiencies and electrolyte 108 
imbalance7. With HG, symptoms can begin earlier in pregnancy than NVP, last 109 
the entire pregnancy and have effects postpartum8,9. The risk of extreme weight 110 
loss during pregnancy (>15% of pre-pregnancy weight) is increased in HG10, as 111 
opposed to the recommended gain of 10-15 kg during pregnancy (given a normal 112 
BMI). In rare cases, nutritional and electrolyte imbalances secondary to HG can 113 
induce cardiac, neuromuscular and renal complications, thyrotoxicosis and have, 114 
even recently, led to maternal death6,11,12. Maternal undernutrition may cause 115 
vitamin K deficiency, which may induce coagulopathy13. Increased risk of 116 
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gestational anaemia has also been reported in HG pregnancies14. HG can also 117 
be associated with Wernicke encephalopathy (brain damage caused by vitamin 118 
B1 deficiency), acute liver and renal failure, splenic avulsion, oesophageal 119 
rupture, valsalva retinopathy (preretinal haemorrhage caused by a sudden 120 
increase in intrathoracic or intraabdominal pressure), pneumothorax, 121 
preeclampsia, and placental abruption15-17. 122 
 123 
NVP may have evolved as a mechanism of pathogen avoidance18,19 and/or 124 
undernutrition resulting in increased placental growth to maintain early 125 
pregnancy20. Despite the prevalence of NVP and the severity of HG, there is a 126 
paucity of research on the pathophysiology, a lack of consensus on diagnosis 127 
and inconclusive evidence on the safety and effectiveness of common 128 
treatments. However, recent advances suggest progress is forthcoming. This 129 
Primer provides a comprehensive review of the current state of knowledge on 130 
NVP and HG. Directions to focus on for future study are also discussed.  131 
 132 
[H1] Epidemiology  133 
 134 
NVP is misleadingly referred to as ‘morning sickness’. Only 1.8% of women 135 
report morning-only symptoms, whereas 80% report all-day nausea21. 136 
Researchers have also described an episodic pattern of NVP, with 95% of 137 
women having symptoms before and after midday22. A meta-analysis quantifying 138 
global rates found 70% of pregnant women experience NVP, with rates varying 139 
widely23. Almost 33% had nausea without vomiting; NVP was rated mild in 40%, 140 
moderate in 46% and severe in 14% of cases, with a 1.1% prevalence of HG23. 141 
Large epidemiological studies that provided the population characteristics of 142 
women with HG, its prevalence, risk factors, impact on perinatal outcome and 143 
recurrence rate have based their estimates entirely on registries14,24-27, which use 144 
unvalidated definitions for HG28. For this reason, these studies are likely to be 145 
subject to considerable imprecision bias, rendering some of their estimates of 146 
limited use (Box 1). Nevertheless, symptoms of NVP are reported in 50–90% of 147 
pregnancies29. Age and gravidity may influence the level of symptoms. Women 148 
<20 years of age, and primigravidas (that is, women who are pregnant for the 149 




The presence or absence of ethnic differences in NVP is less clear. Although 152 
some studies have shown lower rates of symptoms in Africa and Asia compared 153 
with Western countries, others indicate there is no difference30-32. Some of the 154 
inconsistencies have been attributed to the effects of confounding variables such 155 
as household income, parity and oral contraceptive use prior to pregnancy. In a 156 
multivariate analysis aimed at controlling for confounding factors, researchers 157 
noted lower rates of NVP in black and Asian women33.  158 
 159 
Estimated rates of HG vary between 0.3% reported by a Swedish registry to 160 
10.8% noted in a study of pregnancies in China34,35. Ethnic variation in the 161 
incidence of HG is supported by large population studies. A study of 520,739 162 
births in California linked to neonatal discharge data reported a 0.5% incidence of 163 
HG. Within this Californian population, non-white and non-Hispanic patients were 164 
found to have higher rates of HG compared with their white counterparts36. Using 165 
a perinatal database of deliveries in Nova Scotia, a Canadian study found an HG 166 
rate of 0.8%37. In Norway, a population-based study reported an overall 167 
incidence of HG of 0.9%38, but higher rates of HG were noted in subsets of the 168 
Norwegian population (for example, women of Pakistani and Turkish descent). 169 
Women in Norway of Pakistani and sub-Saharan African origin (that is, other than 170 
North Africa) had rates of HG of 2.1% and 3.1%, respectively, whereas women 171 
born in India and Sri Lanka had a reported rate of HG of 3.2% 39. A small study in 172 
northern Israel found a similar prevalence (1.2%) in Arabic and Jewish women40. 173 
In the UK, 2.1% of women were hospitalized for HG, with those of black and 174 
Asian origins more likely to be affected41. A New Zealand study reported a similar 175 
HG rate for people of European descent (2%), but a much higher rate for women 176 
of Pacific Island origin. Within the New Zealand population, Pacific Island women 177 
had an up to four-fold higher rate of HG42. High rates of HG have also been 178 
noted in some Asian populations. For example, a study of patients hospitalized 179 
for hyperemesis in Kuala Lumpur, Malaysia, reported an HG rate of 3.9% and 180 
pregnancies delivered in Osaka, Japan, were associated with an HG rate of 181 
3.6%43,44. Some of the variation in the reported data may be due to 182 
socioeconomic, cultural and/or genetic differences, and inconsistent criteria used 183 




The economic burden of NVP in the United States in 2012 was estimated at 186 
US$1.7 billion45 whereas a recent report from the UK estimated the impact of 187 
NVP on the National Health System to be £62,373,961(Ref46). As many as 18% 188 
of women in the United States take medication for NVP45 and emergency 189 
department visits for NVP are on the rise47,48. A Canadian study from 2007 190 
showed the weekly direct and indirect costs to severe NVP totaled CAN$653 per 191 
patient49. It seems much of this economic burden is unevenly distributed, with 192 
higher rates of NVP reported in women of lower socioeconomic status33,50.  193 
 194 
[H1] Mechanism/pathophysiology 195 
In 1933, NVP was called a ‘disease of theories’51. Although evidence-based 196 
science is still lacking and inconsistent findings have been reported, substantial 197 
progress has been made recently through genetic studies of NVP and HG that 198 
lends support to some of these hypotheses, opening promising new areas of 199 
research into causal factors. A recent review of NVP introduces the pathogenesis 200 
as multifactorial involving genetic, endocrine and gastrointestinal factors52. From 201 
the genetic studies, we now have evidence that supports that these factors are 202 
not mutually exclusive and also implicate placental-mediated mechanisms, 203 
reproductive hormones and gastrointestinal dysmotility, with serotonin and 204 
thyroid hormones potentially involved in rare cases.  205 
 206 
Preliminary evidence that genes play a part in the aetiology of NVP and HG 207 
stems from studies of familial aggregation and twin studies. A threefold higher 208 
risk of HG is apparent in daughters of mothers who had HG53. Sisters of women 209 
who had HG have a 17-fold increased risk of having a pregnancy affected by 210 
HG54. Women with HG have also reported having maternal and paternal 211 
grandmothers affected at equal rates, providing evidence that HG might be 212 
inherited through maternal and/or the paternal lineages54. A twin study estimated 213 
heritability for the presence of NVP to be 73% and for variation in duration and 214 
severity to be >50% (Ref55).  215 
 216 
[H2] GDF15 versus hCG  217 
The prevailing hypothesis in the field has been that the pregnancy hormone 218 
human chorionic gonadotropin (hCG) is central to NVP and HG. This is primarily 219 
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based on the temporal relationship between hCG production and NVP 220 
symptoms, both of which generally peak between gestational weeks 9–12 221 
(Ref52). A review published in 2014 found 18 studies showed increased hCG 222 
levels associated with NVP or HG, whereas 13 studies showed no such 223 
association56. The Generation R study analysed hCG levels in 8,195 women and 224 
found a significant correlation between hCG and daily NVP symptoms57, but a 225 
retrospective cohort study of 4,372 pregnancies following in vitro fertilization 226 
found no evidence of an association between hCG concentrations and HG58.  227 
 228 
A genome-wide association study (GWAS) of >53,000 women of European 229 
descent did not find any evidence to support an association between HG and 230 
hCG. Instead, a region containing the gene GDF15 (encoding 231 
growth/differentiation factor 15) was implicated as a genetic risk factor for both 232 
NVP and HG59. The GWAS also identified the gene encoding the GDF15 233 
brainstem receptor, GFRAL, further implicating the GDF15–GFRAL pathway 234 
(Figure 1). GFRAL is localized to the area postrema (that is, the vomiting centre) 235 
of the brainstem (Box 2) and signals loss of appetite and taste aversion in animal 236 
models60. Interestingly, GDF15 has also been shown to delay gastric emptying61, 237 
which can contribute to nausea in humans62. In a rodent model, GDF15 238 
supplementation resulted in delayed gastric emptying that was abrogated by 239 
vagotomy, suggesting vagal efferents transmit the signal between the brain and 240 
the gut61. In addition, GDF15 is thought to play a part in suppression of maternal 241 
pro-inflammatory cytokines63. However, expression of GFRAL during pregnancy 242 
has not been thoroughly explored and more work must be done to resolve the 243 
issue of whether or not these proteins play a role in immunity during pregnancy. 244 
 245 
Both GDF15 and hCG are hormones that are upregulated in early pregnancy 246 
when NVP and HG symptoms occur64,65. Both are believed to have roles in 247 
placentation and are present in significantly lower levels in women whose 248 
pregnancies end in miscarriage66. However, several additional studies further 249 
implicate GDF15 rather than hCG in NVP and HG. For example, GDF15 causes 250 
loss of appetite and weight loss in animal models via activation of neurons in the 251 
area postrema and hypothalamus through binding to GFRAL60. Abnormal 252 
overproduction of GDF15 is considered a key driver of cachexia, a condition with 253 
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similar symptoms to HG (such as nausea, weight loss and muscle wasting)67,68. 254 
Genetic variants associated with altered expression of GDF15 segregated with 255 
disease in families affected by HG, and were associated with recurrence of HG in 256 
subsequent pregnancies69. Increased maternal serum levels of GDF15 were 257 
associated with maternal antiemetic use and second-trimester vomiting, whereas 258 
hCG levels were not, despite being correlated with GDF15 levels70. Furthermore, 259 
in a separate study, at 12 weeks gestation, GDF15 was found to be significantly 260 
upregulated in the sera of women who were hospitalized for HG compared with 261 
women with NVP71. These conflicting data between hCG serum levels and HG 262 
could be explained by different hCG isoforms52. However, the GWAS study did 263 
not identify any associations between hCG variants and NVP or HG, providing 264 
evidence against this explanation59.  265 
 266 
[H2] IGFBP7 267 
In addition to GDF15, the GWAS implicated additional loci, including a non-268 
coding region neighboring IGFBP7 (encoding insulin-like growth factor-binding 269 
protein 7). IGFBP7 regulates availability of insulin-like growth factors and can 270 
also bind directly to the insulin-like growth factor 1 receptor (IGF1R) to block its 271 
activation72,73. IGFBP7 is involved in implantation and decidualization of the 272 
pregnant uterus, and like GDF15, is significantly upregulated after implantation, is 273 
highly expressed in the developing placenta and is a biomarker for cachexia74,75. 274 
Inhibition of IGFBP7 causes pregnancy loss in a mouse model by shifting uterine 275 
cytokines from helper T type 2 (TH2) to helper T type 1 (TH1) cell dominance, 276 
which represses uterine decidualization and decreases uterine receptivity74. 277 
Additionally, the Drosophila sp. homologue of IGFBP7 has been shown to play a 278 
part in neuronal coordination between metabolic status and feeding behaviour, 279 
potentially signalling food preferences or pregnancy cravings76.  280 
 281 
[H2] PGR 282 
The GWAS implicated an additional region containing PGR (encoding the 283 
progesterone receptor), which has been replicated in an independent cohort77. 284 
PGR may be associated with the normal TH1 to TH2 switch to induce immune 285 
tolerance to fetal antigens and play a part in maintenance of early pregnancy, 286 
similar to the hypothesized role for GDF15 and the substantiated role for 287 
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IGFBP774,78-80. Both PGR and GDF15 have roles in reduced gastrointestinal 288 
motility and gastric dysrhythmias during pregnancy61,81.  289 
 290 
A role for oestrogen and progesterone has been supported by the observation 291 
that women who have NVP or HG are more likely to also experience nausea 292 
while taking contraceptives containing a combination of the two hormones52. As 293 
with hCG, studies of total oestradiol or progesterone and NVP or HG are 294 
conflicting56. Progesterone alone or in combination with oestradiol in non-295 
pregnant women can cause disruption in frequency and direction of gastric 296 
contractions, which may cause nausea82. The mechanism for this disruption is 297 
unknown, but likely involves hormonal signalling that causes a substantial 298 
disruption of slow-wave gastric rhythms. The anorectic and possibly nausea-299 
inducing effects of oestrogen may be due in part to activation of oestrogen 300 
receptor- in the brainstem, which increases the potency of cholecystokinin 301 
(CCK) by increasing the sensitivity of vagal CCK type A receptors in the gut. CCK 302 
slows gastric emptying and activates subdiaphragmatic vagal afferent neurons to 303 
decrease food intake83.  304 
 305 
[H2] Placenta  306 
A role for the placenta rather than the fetus is supported in part due to the 307 
observation that complete hydatidiform mole (a growth typified by placental 308 
development with oedematously enlarged chorionic villi in the absence of an 309 
embryo) can be associated with severe nausea and vomiting84. A report of 310 
anorexia and weight loss in a Rhesus monkey with an ectopic (tubal) pregnancy 311 
consisting of a placenta but no embryo or amnion is also consistent with a 312 
placental role for NVP85. Additional support comes from the observation that NVP 313 
is less common in older women, women with singleton gestation and smokers, 314 
which are all associated with smaller placentas84. Women with HG carrying a 315 
female fetus also had a significantly higher risk of increased placental-weight to 316 
birth-weight ratio (>90th percentile), adding more support to the role of placental 317 
size in HG86.  318 
 319 
However, evidence against a fetal component is supported by the observation 320 
that gestational surrogates carrying fetuses with a maternal history of HG were 321 
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not affected with HG87. Additionally, partner change either does not, or minimally, 322 
affects the risk of recurrence, suggesting a minor role (if any) of paternal genes 323 
expressed in the fetus and/or fetal component of the placenta25,88. A study 324 
showing that consanguinity does not change HG risk also favors maternal genes 325 
over paternal-fetal genes in the aetiology38. Hypothetically, expression limited 326 
primarily to fetally-inherited maternal risk allele(s) could explain the evidence 327 
against a paternal-fetal role while permitting a fetal contribution, but it is currently 328 
unknown whether risk genes are imprinted in the placenta or fetus. Imprinting 329 
studies and studies of fetal inheritance of maternal risk loci may resolve this issue 330 
in the future. For now, the fact that all three risk genes (GDF15, IGFBP7 and 331 
PGR) are expressed in the placenta suggest that the maternal decidual 332 
component of the placenta is likely to be involved in the pathogenesis of NVP 333 
and HG; theoretically, a larger placenta will give rise to more GDF15, IGFBP7 334 
and PGR and these proteins may exacerbate NVP. A fetal and/or paternal 335 
GWAS may help to resolve this issue.  336 
 337 
 338 
[H2] Serotonin receptor 339 
The serotonin receptor has been suggested as a potential aetiological factor 340 
because, like PGR and GDF15, it plays a part in gastrointestinal motility in 341 
humans89. Located in the vagal afferent neurons of the gastrointestinal tract and 342 
vomiting centre (Box 2), the serotonin receptor can activate nausea and vomiting 343 
through serotonin signalling from the gut. Stimulation of the 5‐HT3 subtype of 344 
serotonin receptor (encoded by HTR3C) induces vomiting and 5-HT3 antagonists 345 
are often prescribed to treat NVP and HG90,91. However, 5‐HT3 receptor 346 
antagonists have a beneficial effect in treating NVP and HG in some, but not all 347 
studies52. These drugs possibly block the excitatory receptors located on 348 
sensory, ascending and descending neuronal pathways involved in peristalsis89. 349 
The association between NVP and a rare variant in HTR3C, lends further support 350 
that this receptor may be involved at least in a subset of HG cases92.  351 
 352 
[H2] Thyroid hormones 353 
The association between HG symptoms and thyroid dysfunction in as many as 354 
60% of patients with HG led to speculation that thyroid-stimulating hormone 355 
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receptor (TSHR) may have a role in the condition93,94. Identification of mutations 356 
in TSHR in two patients with HG and gestational thyrotoxicosis (excessive thyroid 357 
hormone) support this hypothesis95,96. However, transient hyperthyroidism is 358 
generally not associated with severity of HG97, primary hyperthyroidism is rarely 359 
associated with vomiting98 and treatment with propylthiouracil, an antithyroid 360 
medication that decreases thyroid hormone by blocking conversion of thyroxine 361 
(T4) to triidiothyronine (T3), does not resolve HG symptoms99. Interestingly, 362 
thyroid hormone has been shown to induce overexpression of RYR2, which 363 
encodes ryanodine receptor 2, a stress-induced calcium channel that has been 364 
associated with cyclic-vomiting syndrome100. The ryanodine receptor family is 365 
expressed in the vomiting centre (Box 2) and has been linked to vomiting as well 366 
as thyroid function90,100. Propranolol, a non-selective beta-blocker used to treat 367 
hyperthyroidism, blocks RYR2 phosphorylation and lowers its expression, and 368 
was used to successfully treat a patient who was hospitalized with HG and 369 
severe thyrotoxicosis100. More work is needed to determine whether thyroid 370 
dysfunction may exhibit an effect on NVP through the RYR2-receptor mediated 371 
vomiting pathway, specifically in those who harbour genetic variants that result in 372 
a ‘leaky’ RYR2 receptor. Along these lines, a whole-exome sequencing study of 373 
five HG-affected families identified new and low-frequency variants in RYR2 that 374 
segregate with disease in two families 100.  375 
 376 
Additionally, patients with hyperthyroidism have significantly increased GDF15 377 
levels, and thyroid hormone treatment upregulates GDF15 expression in mice101. 378 
Thus, thyroid dysfunction may have a role in NVP and HG by contributing to 379 
elevated GDF15 levels. Long-term fasting and nutrient deprivation also contribute 380 
to elevated GDF15 (Refs60,102). Thus, it may be that a combination of genetic 381 
susceptibility, abnormal thyroid hormone levels and low nutrient levels in 382 
pregnancies affected by HG can exacerbate NVP symptoms by increasing 383 
GDF15 (Figure 1).  384 
 385 
[H2] H. pylori and other factors 386 
Several other factors have been implicated in NVP and HG, but their association 387 
may be due to secondary effects. For example, in epidemiological studies, 388 
Helicobacter pylori has consistently been shown to be associated with increased 389 
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occurrence of NVP and HG56,103, and may be associated with severity and 390 
persistence of HG symptoms into the second and third trimester104. However, 391 
some studies find no correlation, and the majority of pregnant women 392 
seropositive for H. pylori do not have HG103. Infection with H. pylori possibly 393 
exacerbate symptoms, but studies are lacking that demonstrate eradication of 394 
infection prior to pregnancy significantly lowers HG risk. It has been suggested 395 
that maternal immunological changes that prevent allogenic rejection of the fetus 396 
may reactivate the bacterium105. Although it remains to be proven, GDF15 and 397 
IGFBP7 may have primary roles in these immunological changes; the same may 398 
be true for other markers showing conflicting results, such as leptin56 and 399 
inflammatory markers, such as CRP106,107.  400 
 401 
In another study, two women affected by HG who had children with riboflavin 402 
deficiency were found to be carriers of SL52A1 mutations108. SLC52A1 encodes 403 
riboflavin transporter-1, which is expressed at high levels in the placenta. The 404 
role it has in the placenta is unknown, but riboflavin (vitamin B2) has a critical role 405 
in energy metabolism. As GDF15 levels are increased in response to nutritional 406 
stress60 and vitamin B2 deficiency has been associated with nausea and 407 
vomiting109, theoretically, vitamin B2 deficiency can signal nausea and vomiting 408 
through upregulation of GDF15.  409 
 410 
[H2] Effects on the mother 411 
In addition to extreme loss of quality of life (QOL), HG can be associated with 412 
substantial maternal risks and outcomes. These outcomes may be related to 413 
prolonged nutritional deficiencies (for example, Wernicke encephalopathy), 414 
electrolyte imbalance (for example hypokalaemia and hyponatremia, which can 415 
contribute to abnormal electrocardiography parameters) and prolonged stress 416 
(for example, post-traumatic stress disorder according to the Diagnostic and 417 
Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-418 
R)). The most-documented nutritional deficiency secondary to HG is vitamin B1 419 
(thiamine) deficiency, which leads to Wernicke encephalopathy and is associated 420 
with ataxia, ocular disturbances and mental status change. Despite the fact that it 421 
is preventable with appropriate thiamine supplementation, reports of Wernicke 422 
encephalopathy are on the rise110. Thiamine has a role in carbohydrate 423 
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metabolism in the brain that is critical to neurological functioning and demands of 424 
thiamine are estimated to increase by >45% during pregnancy. Accordingly, the 425 
inability to eat thiamine-rich foods (such as beef, pork and eggs) or prenatal 426 
vitamins containing thiamine can result in permanent neurological damage to the 427 
mother if left untreated.  428 
 429 
Dehydration can lead to severe electrolyte imbalances, the most frequently 430 
reported, being hypokalaemia. Potassium is required for normal heart and 431 
skeletal muscle contraction. Hypokalaemia can result in a prolonged QT interval 432 
and arrhythmias such as Torsade de pointes, which if left untreated can 433 
degenerate to ventricular fibrillation and cardiac arrest11. In addition to maternal 434 
cardiac arrest, refeeding syndrome and respiratory distress have also been 435 
attributed to severe hypokalaemia in pregnancies affected by HG11.  436 
 437 
There is conflicting evidence regarding other long-term associations including 438 
increased risk of autoimmune disease, breast cancer, and thyroid cancer, but no 439 
association has been found between HG and subsequent cardiovascular risk 111-440 
114. One exploratory study found an increased maternal risk of 7 common 441 
conditions (for example, anxiety and dental cavities) and 50 rare conditions (for 442 
example, blood clots and debilitating muscle weakness) following HG 443 
pregnancies15.  444 
 445 
[H2] Effects on the fetus 446 
Although some evidence suggests that NVP may be associated with favourable 447 
pregnancy outcomes such as lower rates of miscarriage, malformations and 448 
preterm birth115, pregnancies complicated with HG might have poorer perinatal 449 
outcomes, such as low birth weight, small size for gestational age and preterm 450 
birth28. Poorer perinatal outcomes occur in particular in women with little weight 451 
gain during pregnancy or in whom symptoms persist into the second trimester, 452 
suggesting that severe undernutrition retards fetal growth and increases the risk 453 
of perinatal problems37,116. Evidence that severe nutritional deficiency in HG-454 
affected pregnancies can result in adverse fetal outcomes is based on reports of 455 
fetal death secondary to thiamine deficiency in 50% of HG pregnancies affected 456 
by Wernicke encephalopathy110. In addition, reports of vitamin K-deficient 457 
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embryopathy secondary to HG suggest a direct effect of maternal vitamin 458 
deficiency on the developing fetus117,118. A recent cohort study, which is by far 459 
the largest to date with >8 million pregnancies, showed that women who had 460 
been admitted to hospital for HG were more likely to be induced, have a 461 
caesarean section and deliver preterm14. Their babies were more likely to be 462 
small for gestational age and have low birthweight, and also were more likely to 463 
need neonatal care and/or resuscitation. Long-term effects have also been noted 464 
(Box 3).  465 
 466 
[H1] Diagnosis, screening and prevention  467 
Despite the aforementioned challenges in defining HG and difficulties delineating 468 
HG from NVP, current clinical practice is that HG can be diagnosed in a pregnant 469 
woman with severe vomiting and/or severe nausea after other causes have been 470 
ruled out. Other potential causes include gastrointestinal tract conditions (such as 471 
peptic ulcers, appendicitis, obstructions, cholecystitis, pancreatitis and 472 
gastroenteritis), endocrine or metabolic conditions (such as hyperparathyroidism, 473 
hyperthyroidism or diabetic ketoacidosis), neurological conditions (such as 474 
hydrocephalus, tumour in the central nervous system or migraine), drug-induced 475 
or drug-withdrawal nausea, complete hydatidiform molar pregnancy or urinary 476 
tract infection. Definitions of HG are available in practice guidelines but differ in 477 
terms of their symptom requirements and additional criteria (Table 2). For 478 
example, ketonuria, weight loss and gestational age at first presentation of 479 
symptoms are not consistently included in HG definitions5.  480 
 481 
[H2] Diagnosis  482 
A thorough history is the cornerstone in diagnosing HG; laboratory tests are used 483 
to determine the extent of metabolic consequences and to exclude other 484 
diseases.  485 
 486 
[H3]Severity.  487 
The severity of NVP can be assessed using the three-tier Pregnancy-Unique 488 
Quantification of Emesis/nausea (PUQE-24) questionnaire, which includes 489 
questions on the duration of nausea, the number of vomiting episodes, the 490 
occurrence of retching and overall QOL (supplementary Table 1). Symptoms 491 
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during the past 24 hours yield a summary score from 3 to 15; the higher score 492 
the more severe the NVP symptoms. A PUQE score of ≤6 signifies mild NVP, 7–493 
12 signifies moderate NVP and ≥13 equals severe NVP119,120. After antiemetic 494 
treatment and/or hospital treatment for hyperemesis, PUQE scores have been 495 
shown to decrease to levels comparable to those of healthy pregnant women120. 496 
The HyperEmesis Level Prediction (HELP) score121 (supplementary Table 2) 497 
more accurately define the severe symptoms of HG that may be underestimated 498 
using PUQE by adding additional questions such as ability to eat and drink and 499 
weight loss122.  500 
 501 
[H3] Screening.  502 
Screening and early recognition of NVP and HG in primary (general practice) 503 
antenatal care is not routine practice, resulting in lack or delayed onset of 504 
treatment41. At present, ketonuria screening in HG is often used as an aid to 505 
decide on the diagnosis, eligibility for rehydration and eligibility for hospital 506 
admission and discharge. HG is the only example of nausea and vomiting 507 
syndromes in which screening for ketonuria is so widespread and recommended 508 
in guidelines123-125. Ketones in the urine are measured on dipstick. Their 509 
presence indicates lipolysis, which is ‘a measure of starvation’125. However, the 510 
increased metabolic demands of pregnancy, even in the absence of vomiting or 511 
poor oral intake, is a predisposing factor for ketonuria, which Prentice et al.126 512 
coined as ‘accelerated fasting’. A systematic review, including 81 studies of 9 513 
biomarkers as diagnostic tests for HG56 found no evidence for utility of most 514 
biomarkers in diagnosing HG. Interestingly, this study was also unable to find 515 
evidence for the use of ketonuria in establishing the presence or severity of HG. 516 
We, therefore, cannot recommend the use of ketonuria to diagnose HG127.  517 
 518 
A promising new area of study is based on recent research linking GDF15 and 519 
IGFBP7 to HG59,69. A small study showed the combination of elevated serum 520 
levels of both of these proteins at 12 weeks significantly increased the risk of HG 521 
(P=0.0002)71. Larger studies are needed to determine whether combined 522 




[H3] Other abnormalities.  525 
At present, women with potential HG are usually screened for the complications 526 
of prolonged vomiting and poor nutritional intake such as electrolyte 527 
abnormalities, dehydration and weight loss, and sometimes also specific vitamin 528 
deficiencies123,127. In women with HG and neurological symptoms including eye 529 
movement disorders, confusion and/or gait abnormalities, Wernicke 530 
encephalopathy should be considered and neurological assessment and 531 
treatment should be urgently sought128. Wernicke encephalopathy is a clinical 532 
diagnosis, for which defining symptoms are dietary deficiencies, eye movement 533 
disorders, cerebellar dysfunction and an altered mental state (reported as 534 
delirium, confusion and problems in alertness or cognition) and can be supported 535 
by MRI neuroimaging129. 536 
 537 
[H3] Psychological factors.  538 
A pregnancy affected by HG can leave 18% of women affected by postpartum 539 
PTSD (DSM-IV-R), and is more common in women who experience symptoms 540 
for the entire pregnancy9. Screening for symptoms associated with PTSD among 541 
women who have experienced HG may help identify those who may benefit from 542 
psychotherapy130. Specific questions about avoidance, hyperarousal, re-543 
experiencing, dissociation, mood changes and associated functional impairment 544 
can alert clinicians to the possibility of PTSD in postnatal settings131. 545 
 546 
[H3] The fetus. 547 
Especially when women experience severe weight loss or prolonged symptoms, 548 
third trimester ultrasonography screening for fetal growth restriction may be 549 
indicated, as HG increases the risk for this obstetric complication17,132. 550 
 551 
[H2] Prevention 552 
The evidence base for HG preventive measures is, at present, limited but 553 
prevention is the most prudent first step and can begin before conception. A 554 
preconception multivitamin B complex, initiated at the time of fertilization, has 555 
been noted to decrease symptoms and the amount of treatment needed for NVP 556 
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but not for HG133,134. The mechanism is unknown, but may relate to the role B 557 
vitamins play in increasing appetite135 and/or as a rate-limiting co-factor for 558 
synthesis of neurotransmitters including dopamine and serotonin136.  559 
 560 
Having had a previous pregnancy affected by HG is the single largest risk factor 561 
for HG24,26,137. Reports on recurrence of HG in subsequent pregnancies are 562 
widely divergent, ranging from 81% in a small self-selected cohort137 to as low as 563 
15–27% in studies that made used of the International Classification of Disease 564 
(ICD) code-based diagnosis (Box 1)24,26. The clinical implication of unreliable 565 
recurrence rate estimates is that women base their decision to attempt another 566 
pregnancy on their chance of HG recurrence, and may, therefore, be 567 
misinformed about this statistic, possibly misguiding their reproductive choices, 568 
with emotional, economic and medical consequences.  569 
 570 
Nevertheless, prevention of HG in women who experienced HG in their previous 571 
pregnancies might be plausible. For example, a small (n=60) open-label 572 
randomized controlled trial (RCT) in women with a history of severe NVP or HG 573 
showed that pre-emptive combination of doxylamine (an antihistamine) and 574 
pyridoxine (vitamin B6) taken from the time of a positive pregnancy test led to 575 
fewer instances of substantial nausea or vomiting in early pregnancy compared 576 
with treatment after manifest nausea symptoms commenced (15% versus 39%); 577 
the pre-emptive treatment also was associated with a smaller likelihood of 578 
recurrent HG in subsequent pregnancies (32% versus 55%)138. Due to its small 579 
size, lack of extensive baseline characteristics reported, open-label nature and 580 
lack of pre-published protocol, the findings of this study should be interpreted 581 
with caution. On the other hand, the study provides an incentive for further 582 
investigation of preemptive strategies.  583 
 584 
[H1] Management  585 
In general, aspects regarding treatment of NVP and HG are profoundly 586 
understudied, partly hampered by a lack of a distinct definition to compare 587 
studies. Studies regarding lifestyle modifications and complementary therapy are 588 
often small and of poor methodological quality. Even for medical (antiemetic) 589 
treatments and fluid or nutritional therapies, well designed, powered RCTs are 590 
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sparse. Indeed, the Cochrane reviews139,140 conclude that evidence is lacking to 591 
properly determine one treatment as superior to another. The guidelines issued 592 
by the American College of Obstetricians and Gynecologists (ACOG)141 and 593 
Royal College of Obstetricians and Gynaecologists (RCOG)142, as well as this 594 
Primer, are mostly based on lower quality evidence rather than level I evidence.  595 
 596 
Many women will experience a level of NVP that requires some form of 597 
intervention, either non-pharmacological or pharmacological (Figure 2)45. 598 
Interventions can be adjusted according to the frequency and severity of 599 
symptoms. Mild NVP (PUQE ≤6) can be self-managed in the community with 600 
support of primary health care professionals. Moderate NVP (PUQE 7−13) may 601 
respond to complementary therapy but, if no improvement, antiemetics should be 602 
provided. Severe NVP and HG (PUQE >13) will generally need hospital care, 603 
either ambulatory or inpatient to provide fluid and nutritional treatment. As 604 
discussed below, using the PUQE score alone to guide treatment cannot be 605 
recommended, as evaluation of treatment response within the severe category 606 
(which includes HG) has not been specifically evaluated. The HELP score 607 
potentially provides more granular descriptions to guide management, but this 608 
requires further evaluation. 609 
 610 
[H2] Lifestyle modifications 611 
Mild NVP can be addressed with dietary and lifestyle modifications. Small, 612 
frequent meals, higher proportions of proteins and carbohydrates and avoidance 613 
of spicy foods have been reported to provide some symptom relief143,144. An 614 
empty stomach has been noted to increase nausea, so fluids containing 615 
electrolytes are also recommended between meals81,145,146. Adequate rest is 616 
advised in addition to dietary changes to combat the exacerbation of nausea 617 
caused by fatigue147. As there is a general lack of RCTs evaluating lifestyle and 618 
dietary changes and the majority of reviews involve cohort studies of patients 619 
reporting personal preferences, these interventions are only appropriate for 620 
patients with mild NVP. For women with severe NVP or HG, lifestyle and dietary 621 
changes alone are insufficient. 622 
 623 
[H2] Complementary treatment 624 
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When mild symptoms of nausea and vomiting are not relieved by diet and 625 
lifestyle changes alone, other non-pharmacological treatment options are 626 
considered. Ginger has been the most researched and found to be effective for 627 
nausea in pregnancy in some studies140. Gingerols have gastrointestinal motility-628 
enhancing action by acting as dopamine and serotonin antagonists148. ACOG 629 
recommends ginger as first-line non-pharmacological treatment for NVP and 630 
RCOG suggests ginger for women with mild to moderate NVP who wish to avoid 631 
antiemetic therapies141,149. Ginger has been reported as safe to use in the first 632 
trimester and is superior to placebo and pyridoxine139. However, safety studies 633 
for doses >1,000mg/day are lacking and due to potential inhibitory action on 634 
platelet function, ginger is not recommended in patients receiving anticoagulant 635 
therapy150. As with all therapies using herbs or plant extracts, scientific evaluation 636 
and/or comparison of effect is hampered by lack of standardization of actual 637 
active doses.  638 
 639 
Additional non-pharmacological options including acupressure, acupuncture and 640 
electrical nerve stimulation of the P6 point (Neiguan point, located near the wrist 641 
on the inner forearm) have shown varying results140. Acupressure was found to 642 
have similar effects in those with NVP when compared with vitamin B6, but 643 
contrasting results when compared with placebo140. Acupuncture showed 644 
minimal symptom relief in comparison with sham acupuncture whereas electrical 645 
nerve stimulation provided some benefit to patients when compared with 646 
placebo140. However, many of the studies were limited by flawed designs. 647 
Systematic reviews showed no benefit from acupuncture and limited symptom 648 
improvement associated with acupressure105,140. Again, the same difficulty arises 649 
regarding comparison of different types of acupressure or acupuncture; the 650 
pressure or stimulation given to the different parts of the body varies widely.  651 
 652 
Due to expanding legalization of cannabis in the United States, its use in 653 
pregnancy to self-treat NVP, albeit controversial, is on the rise and warrants 654 
discussion151. For example, in Northern California, 7.1% of patients use 655 
marijuana (inhaled and/or edible) in pregnancy (based on self-report and/or 656 
toxicology screens)152. The mechanism of action is unknown, but may act 657 
through its effect on serotonin and dopamine signalling, which can activate the 658 
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vomiting centre153,154. Alongside a growing perception of safety, despite 659 
insufficient evidence152, the self-reported effectiveness of cannabis in treating 660 
NVP is high155. Studies of cannabis use in the context of HG need to establish 661 
efficacy and safety, in consideration of other confounding factors, before any 662 
recommendations can be made in support of its use. Therefore, currently ACOG 663 
recommends against its use141.  664 
 665 
[H2] Pharmacological treatment  666 
Nausea and vomiting are mediated by different mechanisms of activation (Box 2), 667 
but which of these are involved in NVP in general or in individual patients is 668 
unknown156. Theoretically, combining antiemetics with different mechanisms of 669 
action could work synergistically to give the antiemetic effect compared with 670 
changing from one antiemetic to another; this strategy is recommended for 671 
chemotherapy-induced emesis157. Although empirical clinical practice use of 672 
multiple antiemetics to patients with refractory NVP or HG, this strategy has not 673 
been systematically tested in HG and it remains uncertain whether this practice 674 
reduces nausea and/or increases adverse effects for the woman and her fetus.  675 
 676 
The effect of treatment may be monitored using the PUQE score (supplementary 677 
Table 1), or the HELP score (supplementary Table 2) for more severe cases121, 678 
122. However, how well the PUQE score evaluates treatment response in women 679 
in the severe category (likely the dominant part of HG spectrum) is unclear as 680 
this has not been specifically evaluated. Given that the ‘severe’ score is limited to 681 
13–15 points, the PUQE may well be of limited use in these patients, in particular 682 
those with HG. The HELP score was designed in part to address this limitation, 683 
and gives scores from 0-50, with the ‘severe’ group scoring 31–40 and ‘extreme’ 684 
scoring 41–50. Accordingly, the HELP score might provide a robust tool to 685 
evaluate treatment in those with HG. However, this tool is still under initial 686 
evaluation. 687 
 688 
[H3] Antihistamines.  689 
The evidence for antiemetic effectiveness includes a recent study showing 690 
women who were hospitalized for HG were significantly less likely to have been 691 
treated with antiemetics prior to admission than women with HG who were not 692 
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hospitalized41. Additionally, hospitalization rates increased significantly after 693 
removal of combined doxylamine and pyridoxine from the US market due to 694 
unfounded safety concerns. Antihistamines such as doxylamine, dimenhydrinate, 695 
meclizine and promethazine have been used for decades and are the first-line 696 
antiemetics used globally to treat NVP. Antihistamines mainly act on the 697 
vestibular nausea pathway by blocking histamine H1 receptors in the vomiting 698 
centre from communicating with the chemoreceptor trigger zone (Box 2)156. No 699 
harmful fetal effects have been described158. Combined doxylamine and 700 
pyridoxine has been prescribed to treat NVP in Canada for decades, was 701 
approved by the FDA in the United States in 2013 to treat NVP and is gaining 702 
approval elsewhere, expanding to Israel in 2015 and to the United Kingdom in 703 
2018. Approximately 70–80% of women with NVP reported symptom 704 
improvement with the combination, although effectiveness remains 705 
controversial159. Pyridoxine alone was found effective and recommended as one 706 
of the first-line options by ACOG141 but not by RCOG149. ACOG recommends 707 
diphenhydramine as a second-line agent. The combination of diclectin and 708 
pyridoxine combination has been extensively studied, with several reports and 709 
meta-analyses finding no increased risk for fetal malformations160. With 710 
increasing severity of NVP and with HG, other medications are warranted.  711 
 712 
[H3] Neurotransmitter blockade. 713 
Metoclopramide (a dopamine receptor antagonist), dopamine antagonists and 714 
serotonin antagonists have shown variable benefits in clinical trials on NVP. The 715 
dopamine antagonists block dopamine stimulation in the gastrointestinal tract and 716 
the chemoreceptor trigger zone, reducing stimulation of the vomiting centre156. A 717 
Cochrane meta-analysis reviewing 41 clinical trials of NVP treatment (excluding 718 
HG) concluded that none of these antiemetics had documented superior clinical 719 
efficacy compared with each other140. In line with this finding, a Cochrane 720 
analysis of 25 studies for treatment of HG that compared antiemetics pairwise 721 
showed no preferable antiemetic regarding effect but their adverse effect profiles 722 
were different139. Metoclopramide, although not teratogenic, can cause extra-723 
pyramidal reactions (such as dystonia) but this event was mainly reported with 724 
long-term use and primarily in older patients (above traditional reproductive age) 725 
who had other nausea conditions or in those on anticholinergic medication161. 726 
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Hence, without considering the specific indication for use in NVP and/or HG, the 727 
European Medicines Agency (EMA) advises total daily doses as no more than 728 
30mg and use that does not exceed 5 days. Metoclopramide has been 729 
recommended by ACOG as a second-line or third-line option in patients with 730 
persistent symptoms. Other dopamine D2 antagonists such as phenothiazine 731 
derivates (prochlorperazine, promethazine and chlorpromazine) may cause 732 
profound sedation. Newer cohort studies regarding dopamine antagonists have 733 
found no or very low risk for fetal malformations162, 163. Preliminary results 734 
(n=355) are promising for continuous subcutaneous micro-infusions of 735 
metoclopramide; initiated in the hospital, doses are titrated based on the 736 
therapeutic response, after which patients can continue at home164.  737 
 738 
Ondansetron, a selective serotonin 5-HT3 receptor antagonist inhibits serotonin 739 
receptors in the small bowel, vagus nerve and the chemoreceptor trigger zone156. 740 
This antiemetic is used off-label by ~20% of pregnant women in the United 741 
States91,165. In Europe, ondansetron is generally considered a third-line option. A 742 
meta-analysis and review of recent large studies (>76,000 exposures) concluded 743 
ondansetron is not associated with an increased overall risk of any major 744 
congenital malformation, but continued surveillance is warranted particularly for 745 
cleft palate and genitourinary malformations such as hypospadias; future studies 746 
should include gestational age, dose and duration of exposure in the 747 
evaluation166. The studies were unable to comment on the inability of women with 748 
HG to meet nutritional folic acid demands and, therefore, could not assess 749 
whether confounding by indication may have had a role in their findings; folic acid 750 
deficiency is associated with an increased likelihood of oral clefting167. Both 751 
ACOG and RCOG recommend the use of ondansetron as a second-line drug and 752 
the risks of birth defects, although likely to be minimal or due to chance, need to 753 
be discussed with the patients. Prolonged QT interval and serotonin syndrome 754 
may be rare adverse effects153. A US retrospective cohort study found 755 
ondansetron use is linked to fewer miscarriages and terminations and higher live 756 
birth rates compared with women not using ondansetron168.  757 
 758 
[H3] Corticosteroids. 759 
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Corticosteroids are reserved for patients with severe and/or refractory HG, to 760 
achieve anabolism and to act as an adjunct to traditional antiemetics. However, 761 
studies regarding the antiemetic effect of corticosteroids are contradictory. A 762 
network meta-analysis supported the therapeutic benefits of methylprednisolone 763 
in women with refractory HG169. However, a recent Cochrane review showed 764 
corticosteroids provided no difference in hospital duration but did reduce 765 
readmission rates compared with placebo; however, similar readmission rates 766 
were observed when comparing corticosteroids and metoclopramide139. Some 767 
studies show an increased risk of oral clefts with corticosteroid administration 768 
during the first trimester170, but the aforementioned Cochrane review could not 769 
exclude confounding factors such as reduced nutritional intake. Accordingly, 770 
administration of parenteral corticosteroids should preferably be limited to short 771 
durations of treatment and if patients do not respond in 3 days, the medication 772 
should be discontinued. If an adequate response is observed, the dose should be 773 
tapered according to proposed guidelines149. 774 
 775 
[H2] Fluid and nutritional therapy 776 
Severe (PUQE >13) or protracted (>14 days) moderate NVP requires 777 
assessment of the patient’s general condition, extent of weight loss, ketonuria or 778 
dehydration (that is, signs that she has developed HG) and, therefore, 779 
consideration for hospital treatment. Rehydration and/or parenteral nutrition or 780 
tube feeding may be implemented as an outpatient treatment, depending on the 781 
woman’s medical and psychosocial condition, her personal preferences and local 782 
hospital practices105,171. However, the efficacy and safety of nutritional strategies 783 
needs further investigation. 784 
 785 
Fluid volume should be given according to reversal of signs of dehydration and 786 
any electrolyte deficiencies corrected before further parenteral nutritional 787 
interventions. Severe hyponatraemia (<120 mmol/l) should be corrected slowly to 788 
avoid the rare, but potentially severe, complication of central pontine 789 
myelinoysis172. Similarly, hypokalaemia should be corrected slowly to avoid 790 
cardiac arrhythmias. Thiamine should be given when parenteral nutrition is 791 
instituted to reduce the risk of refeeding syndrome and Wernicke 792 
encephalopathy173. For women with continuous vomiting and/or very low food 793 
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intake for >2 weeks, parenteral infusion of  thiamine (100mg in 100ml 0.9% NaCl, 794 
a formulation that differs from most over the counter thiamine supplements) is 795 
recommended before commencing of parenteral treatment, including before 796 
infusing dextrose 10% (the 5% solution is not considered as nutritional 797 
supplementation).  798 
If antiemetics and fluids are not sufficient to reduce the nausea/vomiting, 799 
ketonuria persists, and the patient is unable to improve nutritional intake, 800 
additional nutritional therapy should be considered. Tube feeding is preferred 801 
when prolonged nutritional therapy is needed as it has none of the serious risks 802 
of total parenteral feeding by central venous catheter such as thrombosis, 803 
pneumothorax, phlebitis and sepsis174. Enteral tube feeding may be given by a 804 
gastric tube175 or a jejunal tube positioned by gastroscopy 176,177; a jejunal tube 805 
potentially has less risk of regurgitation of the nutritional solution. The commercial 806 
enteral solutions are ‘complete’ regarding vitamins and trace elements if a daily 807 
dose of 2L is achieved. A Dutch RCT with tube feeding starting on day 1 of 808 
hospital admission for HG did not find significant differences in short or long-term 809 
outcome compared with intravenous rehydration alone175. However, a Norwegian 810 
hospital cohort study  of women whose primary interventions failed and who were 811 
given jejunal tube feeding (n=108) started to regain weight and achieve similar 812 
total maternal weight gain and fetal birth weight as those women not needing 813 
enteral treatment177. Patients may experience tubes as discomforting, demanding 814 
their removal. Otherwise, there are no risks related to enteral tube feeding in 815 
noncomatose patients. 816 
 817 
Parenteral nutritional supplementation (in which the standard manufactured 818 
solutions provide 1,000kcal per litre) may be given by peripheral venous line, but 819 
vitamins and trace elements need to be specifically added before infusion is 820 
started to avoid severe vitamin deficiencies. If total parenteral nutrition is needed, 821 
the patient must be fitted with a central line.  This regimen will need prolonged 822 
hospitalization or specialized home care by infusion nurses.  823 
 824 
[H2] Additional support 825 
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The HG Care Application for iPhone178 was designed for pregnant women taking 826 
medication to treat NVP and to improve patient–provider communication and 827 
care122. It potentially helps with tracking weight loss, symptoms and treatments, 828 
provides reminders to complete the app daily and alerts the patient and/or 829 
provider when symptoms progress, requiring intervention. A beta-testing study122 830 
suggested the app is accurate in defining symptoms and improving 831 
communication and care; a trial is being planned to assess its influence on 832 
outcomes such as emergency room visits (M.S.F.). A similar application, 833 
Symptom Tracking and Reporting (STAR), for measuring symptoms during 834 
chemotherapy, showed patients who used it were significantly less likely to visit 835 
the emergency department or be hospitalized179. Patients can choose to share 836 
their data to alter treatment or for research.  837 
 838 
In addition to these tools, various organizations provide patient support and 839 
management recommendations for patients with HG in several countries (Table 840 
3). These organizations are primarily not-for-profit and patient-run and provide 841 
online and, in some cases, telephone support and information to women with HG, 842 
their providers and families. These organizations also play key parts in research 843 
through participation, conference organization, setting priorities, networking 844 
opportunities, designing treatment protocols, providing content and algorithms 845 
(for example, for the HG Care App), and fundraising. 846 
 847 
[H2] Global variation  848 
Although the majority of published treatment studies are from United States and 849 
Europe and very little from less-resourced settings such as African and Asian 850 
countries, the medical treatment of HG follow the same principles across 851 
continents: antiemetics and intravenous rehydration/electrolyte substitution180,181. 852 
Settings with general lack of access to specialist or hospital care will affect the 853 
availability of infusion therapy and use of relevant antiemetics may be hampered 854 
by lack of medications in stock or being too costly (for example, ondansetron182). 855 
In line with cultural differences in food habits, different herbal remedies are 856 
promoted to alleviate NVP in different countries183,184. In Asia, non-857 
pharmacological management such as acupuncture and acupressure is widely 858 
used for many conditions, including HG185,186. One study describing trends in 859 
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treatment of HG between 1985-2004 in the US, UK, Australia/New Zealand, and 860 
Canada, showed vitamin supplementation ranged from as low as 10% in the UK 861 
to 33% in the US, suggesting two-thirds to as many as 90% of women with HG 862 
may have prolonged vitamin deficiencies187.   863 
 864 
[H2] Quality of life  865 
The PUQE is the best-validated, disease-specific questionnaire for NVP120, which 866 
includes a rating for effects on QOL and for which high scores correlate with 867 
reduced nutritional intake and reduced QOL. Nonspecific QOL scales have 868 
revealed that women with NVP have QOL levels similar to those with breast 869 
cancer or myocardial infarction188. Standardized tools for measuring the 870 
distribution, duration and intensity of nausea showed that severity was 871 
comparable to that induced by moderately nausea-producing chemotherapy, 872 
which is deemed an important adverse effect of treatment that often warrants 873 
intervention, demonstrating that NVP has been widely underestimated21. 874 
Accordingly, the Health-Related Quality of Life for Nausea and Vomiting during 875 
Pregnancy (NVPQOL) was developed as a disease-specific scale189,190. 876 
 877 
A large body of research shows that NVP reduces QOL by negatively affecting 878 
work and family life, physical and mental health and economic well-being191,192. 879 
However, inconsistencies between studies may reflect differences in design, 880 
mode of measurement and sample size; furthermore, when interpreting QOL 881 
results, consideration of environmental, cultural and socio-political aspects is 882 
needed, as well as an understanding that results may not apply to all populations. 883 
Between 37% and 55% of women with NVP lose time at work, and 15.2% of 884 
women with HG terminated at least one pregnancy due to NVP — with inability to 885 
care for self and family as major reasons193,194. Only 1.2% of women have a 886 
history of depression prior to their HG pregnancy195, but HG is associated with 887 
depression and anxiety during pregnancy, and post-traumatic stress following 888 
pregnancy196. The prolonged physical and emotional distress of HG results in an 889 
increased risk of postpartum PTSD (DSM-IV-R), especially when symptoms 890 
persist until term. Indeed, women with HG were more likely to report emotional 891 
distress during pregnancy and up to 6 months post-delivery. However, this 892 
difference disappeared 18 months post-delivery195. Women may limit their family 893 
27 
 
size or turn to other methods (such as adoption and/or surrogacy) to avoid a 894 
subsequent HG-affected pregnancy9,87,137. 895 
 896 
 897 
Despite strong evidence of reduced NVP-related QOL, women experience a lack 898 
of empathy and care, reporting isolation and lack of understanding and support 899 
from healthcare providers197. Clearly, patient satisfaction for these women is 900 
associated with being believed by doctors and health care providers198, 901 
highlighting the need for increased awareness of the NVP burden. Additionally, 902 
24% of patients report never mentioning NVP symptoms to health care 903 
professionals, and two-thirds of general practitioners (GPs) do not address QOL 904 
in pregnancy care199. Moreover, GPs seem to trivialize its symptoms200,201, and 905 
women who have a therapeutic termination of their pregnancy are threefold more 906 
likely to state their medical provider is uncaring or does not understand how sick 907 
they are193. In the United States, most providers taking care of pregnant women 908 
are obstetricians or in family medicine. By contrast, in many European countries, 909 
Australia, New Zealand, and others, GPs are also responsible for family 910 
medicine, providing care to healthy pregnant women in collaboration with other 911 
practitioners, such as midwives. In many of these jurisdictions, pregnant women 912 
are referred to specialist obstetricians only if complications occur. A Norwegian 913 
study identified that attitudes of GPs toward pregnant women hindered 914 
appropriate care for those with NVP; the GP added to the woman’s reluctance to 915 
use antiemetics200. This may reflect past fears of thalidomide use during 916 
pregnancy, which caused infants to be born with limb deformities after women 917 
took the drug for NVP. The majority of women have reported not using anything 918 
to alleviate symptoms, or practices based on previous experience, more than 919 
evidence-based guidelines aiming to improve QOL by treating NVP202.  920 
 921 
[H1] Outlook  922 
Although NVP is a common problem in pregnancy, historically, research into the 923 
condition is lacking. The thalidomide tragedy is responsible, in part, for this 924 
research deficit; the events that took place led to fear of researching, developing, 925 
prescribing and taking medication for use during pregnancy. Another issue is that 926 
NVP is often considered normal and self-limiting, and the burden is largely 927 
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underestimated. However, recent developments suggest a shift in this attitude is 928 
forthcoming. For example, the contribution of patients and patient-led 929 
organizations and charities to research has and will continue to play a key part 930 
moving forward in guiding research priorities, helping with recruitment to clinical 931 
trials and other studies, developing patient–provider partnerships through 932 
organization and support of international conferences, raising funds for research 933 
and providing education and support to the community. One such organization, 934 
the James Lind Alliance, has established Priority Setting Partnerships to prioritize 935 
evidence uncertainties in HG that could be answered by research203. Additionally, 936 
it was women with and those without a history of HG who voluntarily participated 937 
in consumer-driven research by 23andMe that led to the discovery of the first 938 
genes associated with NVP and HG 59.  939 
 940 
The identification of these genes and their abnormal expression levels that confer 941 
risk in affected women opens a new and promising area of research into 942 
understanding the aetiology of NVP and HG. Efforts should focus on 943 
understanding why common variants in genes GDF15, GFRAL, PGR and 944 
IGFBP7 are all confirmed susceptibility loci for NVP and HG. We need to know 945 
whether the proteins encoded by these genes are causal and if so, whether they 946 
can be used for prediction, diagnosis and new treatments for the condition. 947 
Indeed, a GDF15 inhibitor has already proven to successfully restore appetite in 948 
animal models67,61. Drugs targeting the GDF15–GFRAL pathway are under 949 
development to treat cancer-associated cachexia, which is also associated with 950 
abnormally high levels of GDF15 (Refs204,205); this strategy, if proven safe in 951 
pregnancy, may be effective in treating HG. In addition, if drugs can be 952 
developed to target progesterone signalling without effecting pregnancy 953 
outcomes, they may help to treat women with HG. The recent development of an 954 
organoid model for placental development provides a novel reagent for 955 
elucidating the role these factors may have in placental biology206. 956 
 957 
On the subject of genetic testing, although having a family history of HG is 958 
suggestive of a genetic predisposition, it is important to recognize that even if 959 
there is no family history, a genetic predisposition to the disease may still be 960 
present. That is, genetic variant(s) can be inherited down the paternal line or a 961 
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combination of predisposing gene variants and other unknown factors may be 962 
required to predispose to NVP and/or HG. More research is needed to unravel 963 
the genetic and non-genetic components leading to NVP and HG, and 964 
understand how these factors work independently or together to increase 965 
symptoms. Until then, genetic testing will not be very informative. 966 
 967 
In the majority of countries, very few antiemetics are formally approved for NVP 968 
and HG, although combined doxylamine and pyridoxine is increasingly gaining 969 
approvals. As many as 20% of pregnant women in the United States are taking 970 
the off-label drug ondansetron and increasingly using medical marijuana91,165, 971 
which suggests that although fear of medications in pregnancy is subsiding, the 972 
burden of NVP is substantial, and there is a large market for antiemetics to treat 973 
it. And yet, low rates of antiemetic prescriptions are still reported in some 974 
settings, both prior to and upon discharge from the hospital for HG 41,177. 975 
Providers and the patients themselves clearly do not always follow national 976 
recommendations. Thus, more research into the safety and efficacy of the current 977 
treatments for NVP and HG must follow.  978 
 979 
An international consensus on definition is needed for the research to be robust, 980 
for the external validity of study findings and for the possibility of aggregation of 981 
research findings. For example, in the most recent Cochrane review on treatment 982 
of HG139, the authors point out that the variations in definition contributed to 983 
heterogeneity, which hampered their ability to perform meta-analyses, a lament 984 
echoed in other systematic reviews in HG105,207,208. In turn, this lack has slowed 985 
the progress of research in HG treatment. Importantly, the variation in definitions, 986 
or variation in additional criteria, can lead to patients being denied care in some 987 
situations. Unclear definitions can have an impact on patient care, exemplified by 988 
the use of ketonuria as a criterion for treatment. A patient presenting with severe 989 
nausea, frequent vomiting and inability to hold down food and drink, but without 990 
ketonuria, could be unrightfully considered ineligible for treatment with anti-991 
emetics or rehydration.  992 
 993 
It is becoming increasing clear that mother and child are at more risk from leaving 994 
HG untreated than from treatment with most antiemetic therapies. For 995 
30 
 
antiemetics with inconsistent safety data, inclusion of gestational age at exposure 996 
in outcome studies will help determine windows of exposure that may be unsafe. 997 
Alternative routes of administration for antiemetics (such as patches or 998 
suppositories) that cannot be affected by vomiting but still enables patient self-999 
administration are needed. Optimal nutritional regimens should be determined to 1000 
identify which patients benefit from nutritional supplementation and which 1001 
patients only require fluids. More studies must be initiated to determine whether 1002 
early intervention can stop progression of NVP to HG.  1003 
 1004 
Although most providers now recognize HG is a serious condition with a 1005 
biological basis, some providers may need to be better educated to understand 1006 
that patient QOL can improve dramatically with adequate treatment, care and 1007 
understanding. Ignoring the patient can result in serious and long-term maternal, 1008 
fetal and child consequences. The ongoing efforts toward establishing an 1009 
international consensus on the definition of HG and a universal application for 1010 
data collection (for example, with the HG Care App) will improve standardization 1011 
of future studies aimed at properly resolving some of the important issues. They 1012 
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Box 1. Definitions for NVP and HG used in epidemiology and registry 1736 
studies.  1737 
Over the past several decades, the International Classification of Disease (ICD) 1738 
coding for nausea and vomiting of pregnancy (NVP) and hyperemesis 1739 
gravidarum (HG) has increased in its degree of elaboration of the requirements 1740 
for diagnosis to its current (ICD11) definition:  1741 
 1742 
 Mild HG (JA60.0): vomiting occurring during pregnancy responsive to 1743 
dietary modification and antiemetic treatment 1744 
 HG with metabolic disturbance (JA60.1): vomiting in pregnancy, not 1745 
responsive to dietary modification and antiemetic treatment and 1746 
associated with electrolyte disturbances and acid-base imbalance 1747 
 Excessive vomiting in pregnancy, unspecified (JA60.Z) 1748 
 1749 
Although ICD codes accurately reflect the occurrence of life-threatening 1750 
conditions including cardiac arrest and cancer 209,210, the codes have much lower 1751 
diagnostic accuracy for less well-defined conditions, including some obstetric 1752 
diagnoses211. For example, one study looking at the application of ICD8 to ICD10 1753 
codes in Norway showed only 9 out of 14 women (64%) with severe HG (defined 1754 
as hospital admission for HG with weight loss, dehydration and/or ketonuria) 1755 
according to the hospital records could be identified by ICD code. The study also 1756 
showed that codes were incorrectly applied in 5 of 503 (1%) of cases that did not 1757 
have severe HG according to hospital chart212. Other studies have used 1758 
unvalidated registry definitions for HG28. As with other early pregnancy 1759 
conditions, there is an increased likelihood of underreporting due to the design of 1760 
many perinatal registries, which make use of records that are retrospectively 1761 
completed at the point of delivery, and often only include pregnancies >20 weeks 1762 
in gestational age. Any complications that only affected early pregnancy will not 1763 
be registered if the pregnancy ended in miscarriage or termination before 20 1764 
weeks, or if these complications were no longer evident at the time of delivery213. 1765 
Besides being imprecisely reported, HG and termination due to HG214 are 1766 
therefore likely to be underreported in registries. 1767 
 1768 
  1769 
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Box 2. The area postrema (vomiting centre)  1770 
Vomiting is a reflex. Firstly, the gastrointestinal contents are forced back toward 1771 
the oesophagus via retrograde peristalsis. Secondly, there is a deep breath 1772 
followed by closing of the epiglottis to protect the airway. Finally, ejection of 1773 
gastric contents occurs via contraction of the abdomen, diaphragm and 1774 
oesophagus153. The vomiting reflex is controlled by the vomiting centre (the area 1775 
postrema) and the chemoreceptor trigger zone in the medulla oblongata. At least 1776 
five known receptors are involved in feedback to the brainstem: 5-1777 
hydroxytriptamine or 5-HT3 (serotonin), neurokinin NK1 (substance P), 1778 
dopaminergic (D2), histaminergic (H1) and muscarinic M1. These receptors are 1779 
associated with one or more stimulus, including dysmotility and irritation in the 1780 
gastrointestinal tract and lumen; visceral pathology; vestibular disturbance; and 1781 
toxins in the blood or cerebrospinal fluid. Multiple receptors may be affected. For 1782 
example, 5-HT3, NK1, H1, and M1 receptors all play a part in stimulation of the 1783 
vagus nerve of the gut in response to gastrointestinal disturbances, which in turn 1784 
activates the chemoreceptor trigger zone and vomiting centre. Visceral pain, 1785 
anxiety and stress can activate the receptors and signal the vomiting centre by 1786 
providing sensory input through the cerebral cortex. Vestibular disturbances that 1787 
cause, for example, motion sickness, are mediated primarily through H1 and M1 1788 
receptors in the vomiting center. Toxins such as certain drugs or drug 1789 
metabolites can travel through the blood stream to activate 5-HT3, NK1, and D2 1790 
receptors in the chemoreceptor trigger zone. In the vomiting center, at the cellular 1791 
level, vomiting can be achieved via crosstalk between extracellular and 1792 
intracellular receptors. For example, activated 5-HT3 receptors, ryanodine 1793 
receptors, and L-type Ca2+ receptors all release intracellular Ca2+ that cause 1794 
activation of the Ca2+/CamKII-dependent ERK molecular signalling cascade, 1795 
which activates vomiting90. In addition, pathways may interact to exacerbate 1796 
nausea and vomiting. For example, motion sickness can cause anxiety, and 1797 
vagal afferents in the gut also mediate anxiety, which can in turn worsen nausea 1798 
and vomiting215. Finally, the newly discovered receptor GFRAL is localized to the 1799 
vomiting center of the brain where it reduces appetite and causes taste aversion 1800 
when activated by GDF15, but its potential role in vomiting requires further 1801 




Box 3. Long-term effects for the fetus  1804 
The conditions in which the fetus develops have lasting consequences for later 1805 
growth, development and health. Organs and tissues are most sensitive to 1806 
environmental insults such as limited nutrient supply and stress during critical 1807 
periods of development. As HG usually presents during the critical period of 1808 
organ formation and can last the entire pregnancy, it might affect fetal 1809 
development and thereby its later health and wellbeing132. Indications suggest 1810 
that severe NVP and HG negatively affects neurodevelopment of the offspring217 1811 
with potential risks that include development of autism spectrum disorder218, 1812 
attention deficit disorders217, learning difficulties or delays217, psychological 1813 
disorders219, sensory integration or processing disorders217 and social anxiety217. 1814 
However, HG may not have effects on cognitive development217,220. The 1815 
consequences of HG for cardiometabolic health of the offspring may include 1816 
reduced insulin sensitivity and higher blood pressure218, although not all studies 1817 
have demonstrated such an effect221. Baseline cortisol levels may be increased 1818 
in children born from pregnancies with severe HG218. Also, small studies have 1819 
shown a slight increased risk of leukaemia or testicular cancer in offspring of 1820 
affected pregnancies218,222. By contrast, a large Scandinavian registry-based 1821 
study concluded that HG was not associated with increased cancer risk in 1822 
offspring (including leukaemia and testicular cancer), but did find an association 1823 
with lymphoma, which they suggest could be due to chance and needs further 1824 
exploration113. Disease severity and heterogeneous patient populations might 1825 
explain inconsistencies between studies. 1826 
 1827 
Figure 1. Possible model for the role of GDF15 in HG pregnancies.  1828 
Growth/differentiation factor 15 (GDF15) is a hormone produced at the highest 1829 
levels by the placenta (decidual stromal cells and trophoblasts) and is expressed 1830 
as early as the 8–10 cell blastocyst stage223,206,224. Factors including genetic 1831 
variants contribute to altered GDF15 levels59, nutrient deprivation60, long-term 1832 
fasting102 and hyperthyroidism101 may result in a rapid rise and/or abnormally 1833 
high levels in the maternal bloodstream. When GDF15 travels to the area 1834 
postrema and nucleus of the solitary tract (of the medulla oblongata) via the 1835 
circulatory system, it binds to its receptor, GFRAL, where it signals appetite 1836 
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loss216 and taste aversion60. Normally, GDF15 activates GFRAL when the body is 1837 
under physical stress, but when the pathway is overactivated it might also lead to 1838 
nausea and vomiting. Genetic variants of GFRAL are also associated with 1839 
hyperemesis gravidarum (HG)77. Theoretically, in pregnancies affected by HG, 1840 
abnormally high levels of GDF15–GFRAL pathway signalling in the vomiting 1841 
centre (area postrema) of the brainstem may cause appetite loss, taste aversion, 1842 
nausea and vomiting, although this has not been definitively proven. RET is the 1843 
RET Receptor Tyrosine-Protein Kinase that interacts with its co-receptor GFRAL, 1844 
and is required for downstream signalling of appetite loss by GDF15 (Ref216).  1845 
 1846 
Figure 2. Flowchart for the management of NVP and HG 1847 
If the patient presents with mild nausea and vomiting of pregnancy (NVP), dietary 1848 
and lifestyle changes are recommended. If symptoms persist and/or the patient 1849 
presents initially with moderate NVP, complementary treatment is advised 1850 
beginning with non-pharmacological treatment, followed by pharmacological 1851 
intervention if symptoms do not resolve. Patients who present with severe NVP 1852 
or whose symptoms do not improve after second line pharmacological treatment 1853 
will require more aggressive treatment and interventions that may require 1854 
hospitalization. aThe Pregnancy Unique Quantification of Emesis/nausea (PUQE) 1855 
score (supplementary Table 1) is used as a general guideline to roughly assess 1856 
rate of nausea and vomiting, but categories may not apply to all cases, especially 1857 
at the severe end of the clinical spectrum. In particular, the PUQE score may be 1858 
less robust for assessing symptoms in patients with hyperemesis gravidarum 1859 
(HG). Quality of life should also be taken into consideration when determining a 1860 






Table 1. NVP versus HG.  1865 
 1866 
Normal NVP HG 
Minimal weight loss Weight loss >5% 
Adequate intake most days Inadequate intake for weeks or months 
Nausea and vomiting are unpleasant but do 
not limit most essential activities 
Nausea and vomiting cause misery and often 
limit daily activities including self-care 
Dietary and lifestyle changes make symptoms 
mostly manageable 
Medical treatments, such as medications and 
intravenous therapy, are needed 
Symptoms generally ease considerably by 14 
weeks gestation 
Symptoms may ease or persist until delivery 
Family responsibilities can be completed most 
days, especially after 14 weeks gestation 
Family responsibilities are very difficult or 
impossible to complete for weeks to months 
NVP, nausea and vomiting of pregnancy; HG, hyperemesis gravidarum. Used with permission 1867 
from K. MacGibbon, Hyperemesis Education and Research Foundation. [CE: please update 1868 
permission line, iLTP received] 1869 
 1870 
Table 2. Clinical definitions of hyperemesis gravidarum in practice 1871 
guidelines 1872 
 1873 
Guideline Required criteria Additional criteria Ref 
RCOG Green Top 
Guideline 
 Protracted nausea and/or 
vomiting 
 Onset in the first trimester 
 No other causes identified  







Persistent vomiting in the 
absence of other diseases that 
could explain findings 
 Ketonuria 
 Weight loss >5%  
 Electrolyte 
abnormalities 





Persistent vomiting in 
pregnancy 





ACOG, American College of Obstetricians and Gynecologists; RCOG, Royal College of 
Obstetricians and Gynaecologists; SOGC, Society of Obstetricians and Gynecologists of Canada.  
 1874 
  1875 
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Table 3. Organizations that are sources of education, support, research, 1876 
fundraising, and other resources related to NVP and HG. 1877 
 1878 
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Supplementary Table 1. Modified Pregnancy-Unique Quantification of 1882 
Emesisa  1883 
Circle the answer that best suits your situation for the last 24 hours 
1. On average in a day, how long do you feel nauseated or sick to your stomach? 
>6 hours 4-6 hours 2-3 hours ≤1 hour Not at all 
5 points 4 points 3 points 2 points 1 point 
2. On average in a day, how many times do you vomit or throw up? 
≥ 7 times 5-6 times 3-4 point 1-2 points Not at all 
5 points 4 points 3 points 2 points 1 point 
3. On average in a day, how many times do you have retching or dry heaves without 
bringing anything up? 
≥ 7 times 5-6 times 3-4 point 1-2 points Not at all 
5 points 4 points 3 points 2 points 1 point 
     
Total score 
(sum of replies 
to 1, 2 and 3)  
≤6 Mild NVP 7-12 Moderate 
NVP 
≥13 Severe NVP  
 
Quality of life question 
On a scale of 1 to 10, how would you rate your well 
being? 
0 = worst possible  
10 = as good as you felt before 
pregnancy 
Adapted from Refs1,2.a The original PUQE was a 12-hour assessment and 1884 
this is modified to cover a 24-hour period]  1885 
1. Koren, x et al. J. Obstet. Gyn. xx 1886 
2. Lacasse, x et al. AJOG xx  1887 
To the editor:I attached separately the document Jone sent related to this-1888 
she said: I have attached a dokument displaying the different PUQE-figures and 1889 
appropriate references, to use for how to properly use and cite for «our» PUQE-figure. 1890 
Perhaps best to discuss with Mina as she is the professional in what is the correct way 1891 
regarding copyright/citations?] 1892 
  1893 
  1894 
53 
 
Supplementary Table 2. The HyperEmesis Level Prediction (HELP) Score to 1895 




HG, hyperemesis gravidarum; NVP, nausea and vomiting of pregnancy. Used with permission 1900 
from Kimber MacGibbon, RN, Director, Hyperemesis Education and Research Foundation. [CE: 1901 
please update permission line, iLTP received] 1902 
 1903 
